Baseline tumour burden and prognosis in breast cancer treated with immune checkpoint inhibitors
Baseline tumour burden assessed by BTS and TTB is significantly associated with prognosis in advanced breast cancer treated with ICI and should be considered a potential biomarker to improve selection of patients for treatment with ICI. These results suggest that ICI treatment will be most effective in patients with lower tumour burden.
Authors
- Sherene Loi (ORCID: https://orcid.org/0000-0001-6137-9171)
- Steven David (ORCID: https://orcid.org/0000-0001-6370-5233)
- Prudence A. Francis (ORCID: https://orcid.org/0000-0002-7207-9286)
- Kate Moodie (ORCID: https://orcid.org/0000-0002-8414-6052)
- Peter Savas (ORCID: https://orcid.org/0000-0001-5999-428X)
- Courtney T. van Geelen (ORCID: https://orcid.org/0000-0002-2716-9135)
- Julia R Dixon-Douglas (ORCID: https://orcid.org/0000-0003-1896-5604)
- Lauren Brown (ORCID: https://orcid.org/0000-0002-3598-5810)
Institutions
- Inserm (FR)
- Peter MacCallum Cancer Centre (AU)
- Institut Gustave Roussy (FR)
Publication Details
- Journal
- The Breast
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1016/j.breast.2025.104586
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00